A Randomazed, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension

• Sitting Systolic Blood Pressure [ Time Frame: at 4 and 8 weeks from Baseline visit ] [ Designated as safety issue: Yes ]
  To compare the difference of Sitting Systolic Blood Pressure at 4,8 weeks from baseline visit
• Sitting Diastolic Blood Pressure [ Time Frame: 4weeks from baseline visit ] [ Designated as safety issue: Yes ]
  To compare the difference of Sitting Diastolic Blood Pressure at 4 weeks from baseline visit
• Responder ratio [ Time Frame: at 8weeks from baseline visit ] [ Designated as safety issue: Yes ]
  To compare the ratio or responder(SiDBP<90mmHg or difference of SiDBP>10mmHg from baseline) at 8 weeks

The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan

• Placebo Comparator: Placebo
  Take one double-blind capsule filled with a placebo tablet in the everymorning
  Intervention: Drug: Fimasartan , Amlodipine, Placebo
• Active Comparator: Fimasartan 60mg
  Take one double-blind capsule filled with of Fimasartan 60mg in the everymorning
  Intervention: Drug: Fimasartan , Amlodipine, Placebo
• Active Comparator: Fimasartan 30mg
  Take one double-blind capsule filled with Fimasartan 30mg in the everymorning
  Intervention: Drug: Fimasartan , Amlodipine, Placebo
• Active Comparator: Amlodipine 5mg
  Take one double-blind capsule filled with Amlodipine 5mg in the everymorning
  Intervention: Drug: Fimasartan , Amlodipine, Placebo
• Active Comparator: Amlodipine 10mg
  Take one double-blind capsule filled with Amlodipine 10mg in the everymorning
  Intervention: Drug: Fimasartan , Amlodipine, Placebo
• Experimental: Fimasartan 60/ Amlodipine 5mg
  Take one double-blind capsule filled with Fimasartan 60mg and Amlodipine 5mg in the everymorning
  Intervention: Drug: Fimasartan , Amlodipine, Placebo
• Experimental: Fimasartan 60/Amlodipine 10mg
  Take one double-blind capsule filled with Fimasartan 60mg and Amlodipine 10mg in the everymorning
  Intervention: Drug: Fimasartan , Amlodipine, Placebo
• Experimental: Fimasartan 30/Amlodipine 5mg
  Take one double-blind capsule filled with Fimasartan 30mg and Amlodipine 5mg in the everymorning
  Intervention: Drug: Fimasartan , Amlodipine, Placebo
• Experimental: Fimasartan 30/Amlodipine 10mg
  Take one double-blind capsule filled with Fimasartan 30mg and Amlodipine 10mg in the everymorning
  Intervention: Drug: Fimasartan , Amlodipine, Placebo

Inclusion Criteria:

1. Subjects who agreed to participate in this study and submitted the written informed consent
2. Subjects aged 20 to 75 years
3. Essential hypertension subjects who are measured more 95mmHg, less than 114mmHg of sitting diastolic blood pressure (SiDBP) at baseline(day 0).
4. Subjects who considered to understand this study , be cooperative, and able to be followed-up whole of the study period.

Exclusion Criteria:

1. Severe hypertension patients; more 115mmHg of SiDBP and/or more 185 mmHg of Sitting systolic blood pressure (SiSBP)
2. Patients with secondary hypertension
3. Patients with significant investigations - abnormal renal function (Creatinine more 1.5 times than upper limit of normal), abnormal liver function (AST, ALT more 2 times than upper normal), moderate fatty lever needed medication
4. Patients with significant investigations - Hypokalemia(Less than 3.5mmol/L), Hyperkalemia(exceeded 5.5mmol/L)
5. Patients witn sodium ion or body fluid is deplated and not able to correct
6. Patients with hypotension who has sign and symptom
7. Patients with surgical and medical disease it is able to be affect to absorption, distribution, metabolism, excretion
8. Patients with severe insulin dependent or uncontrolled diabetes mellitus (HbA1c > 9%, regimen change of oral hypoglycemic agent, using insulin)
9. Patients with severe heart disease, ischemic heart disease within 6months, peripheral vascular disease, Percutaneous Transluminal Coronary Angiography (PTCA), Coronary Artery Bypass Graft (CABG)
10. Patients with significant ventricular tachycardia, atrial fibrillation, atrial flutter or other significant arrhythmia
11. Patients with hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, hemodynamically significant aortic valve or mitral valve disease
12. Patients with severe cerebrovascular disease
13. Patients with wasting disease, autoimmune disease, connective tissue disease at present and/or previous.
14. Patients with known severe or malignancy retinopathy
15. Patients with hepatitis B or C or HIV positive reaction
16. Patients who have a story or evidence of alcohol or drug abuse within 2years
17. Patients who are measured the mean difference of mean blood pressure of both arm under SiDBP 10mmHg or SiSBP 20mmHg at screening and baseline visit
18. Patients with history of allergic reaction to any angiotensin II antagonist
19. Patients with any chronic inflammation disease needed to chronic inflammation therapy
20. Patients with the medical histories of malignant tumor within 5years, except local basal cell carcinoma of the skin
21. Childbearing and breast-feeding women
22. Female who plan to become pregnancy or have a possibility of pregnancy but don't prevent conception with acknowledged methods
23. Patients who took medicine within 12 weeks from screening visit or is going on the progress of other clinical trial
24. Subject who are judged unsuitable to participate in this study by investigator

• Gachon University Gil Medical Center
• The Catholic University of Korea
• Gyungbook national university hospital
• Gyemyung university hospital
• Daegu Catholic university hospital
• Wonkwang university Hospital
• Yonsei University Wonjoo Christian Hospital
• Korea University Guro Hospital
• DongGuk University Ilsan Hospital
• Yeungnam University
• Chonnam National University Hospital
• Cheil General Hospital and Women’s Healthcare Center
• Chungnam National University
• Asan Medical Center
• Seoul National University Bundang Hospital
• Inha University Hospital
• Seoul National University Hospital
• Inje University Busan Beak Hospital
• Samsung Medical Center
• Busan university Yangsan Hospital